ONC201, an anti-cancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers including mantel cell lymphoma (MCL) and acute myeloid leukemia (AML), according to a recent clinical study.

Source: First-in-class drug ONC201 shows potential for some blood cancers


David Cottle

UBB Owner & Administrator